is only 12% of the overall exposure to ionising radiation,8 it is almost 90% of the exposure from man made sources.9 Indeed, the annual exposure of the British population from diagnostic radiology is eight times the exposure it received from Chernobyl in the year after the accident.
Attention has long been paid to technical methods of reducing the radiation dose from diagnostic radiology, and the new report contains much technical detail. But for doctors the importance of the report lies more in the general principles. '°The first principle of radiation protection is that all examinations must pass a cost-benefit analysis: if they don't then they shouldn't be done. A second principle applies to the dose delivered if an examination is warranted and has been called the ALARA (as low as reasonably achievable) principle.
The report suggests that a fifth of radiographic examinations carried out in Britain are clinically unhelpful. Elimination of such examinations would give a potential annual collective dose saving of 3200 man Sv. The missing radiograph is another cause of unnecessary exposure, and a survey in an orthopaedic clinic reported that a third of all patients had repeat examinations because of missing films -a bland statement of a shocking fact. Repeat rates of between 3% and 15% have been reported and should be reduced by quality control procedures. LONDON, SATURDAY 8 SEPTEMBER 1990 The wide variations in the skin dose among patients and among patients in different rooms shown by the National Radiological Protection Board survey" means that some hospitals are exercising tighter control over the range of doses delivered for a particular examination than others. The report suggests that hospitals with mean dose values lying, for example, in the upper quartile of those reported in the survey are using inefficient techniques. The report recommends that all radiography departments should aim to achieve mean dose values less than a set of reference doses given in the report. Reducing hospital doses in this way would produce an annual collective dose saving of 1300 man Sv. Reducing fluoroscopy time should achieve a further reduction of 1500 man Sv. The overall saving from these patient oriented methods amounts to 7500 man Sv a year, and the great importance is that it may be achieved at no net cost.
Other ways of reducing the radiation depend on adapting equipment and cost money. Their justification thus requires careful application of the cost-benefit principle. [12] [13] [14] The report states that various aspects of equipment choice that lie within the purlieu of the radiography departments may save a further 9000 man Sv annually. The cost would vary from zero in the cases of rare earth screens, wherethe cost is discounted against other savings, to £1 10-280 for each man Sv. This is many orders ofmagnitude less than the cost ofequivalent dose reductions in the nuclear power industry.
There are two recommendations in the report that are particularly important to the average doctor. Firstly, they should know about a booklet prepared by a study group of the Royal College of Radiologists Making the Best Use of a Department of Radiology.'5 Secondly, all employment related radiological screening programmes should be clinically justified and the reasons for screening explained in writing to the employees. For those managing departments ofradiology, the report emphasises the value of acceptance testing of radiographic equipment and of regular quality control checks.
The report also draws attention to the benefits ofalternative modalities avoiding x rays and concludes that Britain is lagging behind other developed countries in providing magnetic resonance imaging. The report ends by drawing attention to the requirement for adequate training laid down under the lonising Radiation (Protection of Persons Undergoing Diagnosis or Treatment) Regulations 1988 and recommends that the core of knowledge required under these regulations BMJ VOLUME 301should be incorporated into the medical undergraduate curriculum. This is already the case in some medical schools. 
Osteoporosis after 60
Advice needs to be individual At and around the menopause many women who wish to protect their future skeletal health use oestrogen (plus progestogen) as the therapeutic cornerstone, supported by exercise and plentiful calcium."'3 The predictive relation between bone mineral content and subsequent fracture now identifies those most at risk.4 Hormone replacement treatment is no longer a first choice, however, for the over 60s, in whom most of the skeletal damage has been done2 and often the first fracture has occurred. Oestrogen may still prevent the loss of bone at this age,5 but the risks of a decade of hormone replacement treatment are largely unknown,6 and for most women with an intact uterus the intermittent bleeding produced by cyclical treatment with oestrogen and progestogen is no longer acceptable. What women require during these later years is an agent that increases bone formation and decreases its rate of fracture. Sodium fluoride, the most realistic candidate, is out of favour7; the original diphosphonate, etidronate, now shows promise.8
The fluoride ion stimulates activity of the osteoblasts and increases the density of trabecular bone, but not all patients respond, distressing gastrointestinal and skeletal side effects may occur, and appendicular bone may be at risk.7 If the large induced increases in vertebral density were mirrored by equally impressive declines in fracture rate, however, such disadvantages could be outweighed. Are they?
The results of a multicentre French study of 466 postmenopausal women with osteoporosis (aged 50-92) support this possibility. In those 257 women who took fluoride (sodium fluoride 50 mg daily, equivalent to 22-6 mg fluoride ion) the incidence of vertebral crush fractures was lower at 12 and 24 months than that in those having regimens without fluoride. All took 1000 mg of added calcium and 800 IU of vitamin D-2 daily.9
By contrast, a four year randomised prospective study from the Mayo Clinic of 202 postmenopausal women with osteoporosis (average age 68) showed no reduction in vertebral fractures in the group taking fluoride despite the expected appreciable increase in mineral density.'0 Sodium fluoride was given as 60 and 90 mg on alternate days; all received additional calcium (1500 mg daily). The total incidence of non-vertebral fractures (complete plus incomplete) increased, and the cortical bone mass (mid-shaft radius) decreased in the group receiving fluoride. Interestingly, in the group receiving only 1500 mg calcium the spinal bone density did not show the expected decrease with time.
These findings and other similar results" have dampened enthusiasm for fluoride-and, incidentally, have increased it for calcium. But the cumulative individual dose of fluoride in the Mayo study was three times that in the French, and such a dose might well be toxic. With etidronate, too, dose is important as at 20 mg/kg a day bone mineralisation is delayed.'2 Unlike fluoride, etidronate does not stimulate the osteoblast: instead it suppresses the osteoclast. In a double blind Danish investigation of 66 postmenopausal women with osteoporosis (mean age 68) oral etidronate was given in a dose of 400 mg daily in cycles (two weeks on, 13 weeks off, repeated for 150 weeks) with 500 mg calcium and 400 IU vitamin D a day continuously. At the end of this time vertebral bone mineral density in the group taking etidronate had increased and the rate of vertebral fracture was lower than in the group taking placebo between the 60th and 150th week.8 A subsequent American study confirmed these findings. 13 How do these changes come about? And are they likely to be sustained? Osteoblasts and osteoclasts communicate with each other, so that when bone resorption is suppressed bone formation also falls-but only months later. During this time any antiresorptive agent, such as calcitonin, will increase bone mass as osteoblasts overfill the shallowed resorptive lacunae. 14 This effect is only temporary, but in theory one could produce a cumulative increase in bone density by dissociation between the osteoblast and osteoclast at each etidronate cycle. This has to be shown.
Where does all this leave the doctor? No magic treatment predictably rebuilds the aging skeleton. Fluoride cannot be recommended, and etidronate needs more work. Calcitonin by injection is not universally effective or acceptable, and more work is needed on nasal preparations.'5 Each patient requires reassurance and explanation, especially after the first fracture. Physical activity,'6 supplemental calcium (despite continuing controversy7-'9), and the avoidance of risk factors such as smoking and excessive alcohol remain important. 
